CD8A and neoplasm: The feasibility of this approach was demonstrated by the ability of IMP321, a soluble LAG-3 fusion protein capable of binding to MHC-II, to inhibit tumor growth in vivo, significantly activating CD8+ T cells, and extending PFS in patients with advanced renal cancer (73).